News Image

Global Cancer Rates Surge as Biotech Innovators Work on New Therapies

Provided By PR Newswire

Last update: Sep 20, 2024

Issued on behalf of Oncolytics Biotech Inc.

VANCOUVER, BC, Sept. 20, 2024 /PRNewswire/ -- USA News Group – Cancer rates are rising globally, and the outlook is particularly concerning for men. A recent global study projects an 84% increase in cancer cases and a 93% rise in cancer deaths among men by 2050. According to Our World in Data, cancer has overtaken cardiovascular diseases as the leading cause of death in several wealthy nations. Despite warnings from the American Cancer Society, which found that 44% of cancer deaths in U.S. adults are linked to lifestyle factors, troubling trends continue. Another study revealed that even light drinking is associated with an increase in cancer deaths among older adults in Britain. Meanwhile, behind the scenes, biotech innovators are developing new targets for improved cancer therapies, driving the next wave of breakthroughs in oncology coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), G1 Therapeutics, Inc. (NASDAQ: GTHX), Arcellx, Inc. (NASDQ: ACLX), Sanofi (NASDAQ: SNY), and Halozyme Therapeutics, Inc. (NASDAQ: HALO).

Read more at prnewswire.com

SANOFI-ADR

NASDAQ:SNY (2/21/2025, 8:00:02 PM)

After market: 54.46 0 (0%)

54.46

+0.33 (+0.61%)


ONCOLYTICS BIOTECH INC

NASDAQ:ONCY (2/21/2025, 8:00:01 PM)

After market: 0.71 -0.02 (-2.15%)

0.7256

-0.01 (-1.79%)


HALOZYME THERAPEUTICS INC

NASDAQ:HALO (2/21/2025, 8:25:06 PM)

After market: 56.89 -0.86 (-1.49%)

57.75

+0.31 (+0.54%)



Find more stocks in the Stock Screener

Follow ChartMill for more